Tectonic Therapeutic, Inc. Common StockTECX
About: Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Employees: 51
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
257% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 7
63% more capital invested
Capital invested by funds: $217M [Q3] → $355M (+$137M) [Q4]
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
35% more funds holding
Funds holding: 52 [Q3] → 70 (+18) [Q4]
3.4% more ownership
Funds ownership: 48.72% [Q3] → 52.11% (+3.4%) [Q4]
60% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 2 (-3) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Mizuho Uy Ear 29% 1-year accuracy 2 / 7 met price target | 161%upside $51 | Outperform Initiated | 21 Apr 2025 |
Wells Fargo Tiago Fauth 30% 1-year accuracy 8 / 27 met price target | 417%upside $101 | Overweight Maintained | 21 Mar 2025 |
Financial journalist opinion









